Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fagan, 2007, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, Arch Neurol, 64, 343, 10.1001/archneur.64.3.noc60123
Shaw, 2009, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol, 65, 403, 10.1002/ana.21610
Li, 2007, CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa
Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064
Visser, 2009, Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol, 8, 619, 10.1016/S1474-4422(09)70139-5
Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009
Rowe, 2010, Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, Neurobiol Aging, 31, 1275, 10.1016/j.neurobiolaging.2010.04.007
Villemagne, 2011, Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease, Ann Neurol, 69, 181, 10.1002/ana.22248
Fagan, 2009, Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly, Ann Neurol, 65, 176, 10.1002/ana.21559
Jagust, 2010, The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core, Alzheimers Dement, 6, 221, 10.1016/j.jalz.2010.03.003
Dickerson, 2012, MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults, Neurology, 78, 84, 10.1212/WNL.0b013e31823efc6c
Vemuri, 2009, MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations, Neurology, 73, 287, 10.1212/WNL.0b013e3181af79e5
Desikan, 2009, Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease, Brain, 132, 2048, 10.1093/brain/awp123
DeCarli, 2007, Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia, Arch Neurol, 64, 108, 10.1001/archneur.64.1.108
Grundman, 2002, Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial, J Mol Neurosci, 19, 23, 10.1007/s12031-002-0006-6
Fleisher, 2005, Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment, Arch Neurol, 62, 953, 10.1001/archneur.62.6.953
Jack CR Jr. Measuring progression of AD with imaging: outcome measures for trials. International Conference on Alzheimer's Disease; Vienna, Austria; July 11–16, 2009. S1–03.
Jack, 2010, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade, Lancet Neurol, 9, 119, 10.1016/S1474-4422(09)70299-6
Strozyk, 2003, CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, 652, 10.1212/01.WNL.0000046581.81650.D0
Tapiola, 2009, Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch Neurol, 66, 382, 10.1001/archneurol.2008.596
Ikonomovic, 2008, Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, Brain, 131, 1630, 10.1093/brain/awn016
Kantarci, 2010, Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies, Neurobiol Aging, 33, 878, 10.1016/j.neurobiolaging.2010.08.007
Fleisher, 2011, Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch Neurol, 68, 1404, 10.1001/archneurol.2011.150
Sojkova, 2011, In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults, Arch Neurol, 68, 232, 10.1001/archneurol.2010.357
Buerger, 2006, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain, 129, 3035, 10.1093/brain/awl269
Buchhave, 2012, Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia, Arch Gen Psychiatry, 69, 98, 10.1001/archgenpsychiatry.2011.155
Fagan, 2009, Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease, EMBO Mol Med, 1, 371, 10.1002/emmm.200900048
Bobinski, 2000, The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease, Neuroscience, 95, 721, 10.1016/S0306-4522(99)00476-5
Zarow, 2005, Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia, Ann Neurol, 57, 896, 10.1002/ana.20503
Jack, 2002, Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia, Neurology, 58, 750, 10.1212/WNL.58.5.750
Vemuri, 2008, Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage, Neuroimage, 42, 559, 10.1016/j.neuroimage.2008.05.012
Whitwell, 2012, Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study, Lancet Neurol, 11, 868, 10.1016/S1474-4422(12)70200-4
Whitwell, 2008, MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study, Neurology, 71, 743, 10.1212/01.wnl.0000324924.91351.7d
Josephs, 2008, Beta-amyloid burden is not associated with rates of brain atrophy, Ann Neurol, 63, 204, 10.1002/ana.21223
DeCarli, 1992, Postmortem regional neurofibrillary tangle densities, but not senile plaque densities, are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease, Neurodegeneration, 1, 113
Ingelsson, 2004, Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain, Neurology, 62, 925, 10.1212/01.WNL.0000115115.98960.37
Perrin, 2009, Multimodal techniques for diagnosis and prognosis of Alzheimer's disease, Nature, 461, 916, 10.1038/nature08538
Mormino, 2009, Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects, Brain, 132, 1310, 10.1093/brain/awn320
Jack, 2008, 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, 665, 10.1093/brain/awm336
Jack, 2009, Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease, Brain, 132, 1355, 10.1093/brain/awp062
Hyman, 2011, Amyloid-dependent and amyloid-independent stages of Alzheimer disease, Arch Neurol, 68, 1062, 10.1001/archneurol.2011.70
Fox, 1999, Correlation between rates of brain atrophy and cognitive decline in AD, Neurology, 52, 1687, 10.1212/WNL.52.8.1687
Jack, 2000, Rates of hippocampal atrophy correlate with change in clinical status in aging and AD, Neurology, 55, 484, 10.1212/WNL.55.4.484
Rabinovici, 2008, Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia, Ann Neurol, 64, 388, 10.1002/ana.21451
Wolk, 2012, Amyloid imaging in dementias with atypical presentation, Alzheimers Dement, 8, 389, 10.1016/j.jalz.2011.07.003
Ridha, 2006, Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study, Lancet Neurol, 5, 828, 10.1016/S1474-4422(06)70550-6
Jack, 2008, Atrophy rates accelerate in amnestic mild cognitive impairment, Neurology, 70, 1740, 10.1212/01.wnl.0000281688.77598.35
Stern, 2006, Cognitive reserve and Alzheimer disease, Alzheimer Dis Assoc Disord, 20, S69, 10.1097/00002093-200607001-00010
Nelson, 2010, Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons, Brain Pathol, 20, 66, 10.1111/j.1750-3639.2008.00244.x
Jack, 2011, Evidence for ordering of Alzheimer disease biomarkers, Arch Neurol, 68, 1526, 10.1001/archneurol.2011.183
Lo, 2011, Longitudinal change of biomarkers in cognitive decline, Arch Neurol, 68, 1257, 10.1001/archneurol.2011.123
Forster, 2012, Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay, Biol Psychiatry, 71, 792, 10.1016/j.biopsych.2011.04.023
Landau, 2012, Amyloid deposition, hypometabolism, and longitutdinal cognitive decline, Ann Neurol, 72, 578, 10.1002/ana.23650
Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N Engl J Med, 367, 795, 10.1056/NEJMoa1202753
Chen K, Quiroz Y, Jakimovich L, et al. Age-associated trajectories of biomarkers in early-onset Alzheimer's disease, for the Alzheimer's Prevention Initiative. Alzheimer's Association International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 01-01-04.
Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol, 59, 512, 10.1002/ana.20730
Caroli, 2010, The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol Aging, 31, 1263, 10.1016/j.neurobiolaging.2010.04.024
Sabuncu, 2011, The dynamics of cortical and hippocampal atrophy in Alzheimer disease, Arch Neurol, 68, 1040, 10.1001/archneurol.2011.167
Schuff, 2012, Nonlinear time course of brain volume loss in cognitively normal and impaired elders, Neurobiol Aging, 33, 845, 10.1016/j.neurobiolaging.2010.07.012
Jack, 2012, Shapes of the trajectories of 5 major biomarkers of Alzheimer disease, Arch Neurol, 69, 856
Jack CR Jr, Wiste HJ, Lesnick T, et al. Brain beta amyloid load approaches a plateau. Neurology (in press).
Thurfjell L, Lundqvist R, Villemagne VL, Rowe CC. A data-derived Aβ biomarker model computed using longitudinal PiB data from AIBL. Alzheimer's Association International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 03-12-01.
Troncoso, 2008, Effect of infarcts on dementia in the Baltimore longitudinal study of aging, Ann Neurol, 64, 168, 10.1002/ana.21413
Schneider, 2009, The neuropathology of probable Alzheimer disease and mild cognitive impairment, Ann Neurol, 66, 200, 10.1002/ana.21706
Markesbery, 2006, Neuropathologic substrate of mild cognitive impairment, Arch Neurol, 63, 38, 10.1001/archneur.63.1.38
White, 2009, Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study, J Alzheimers Dis, 18, 713, 10.3233/JAD-2009-1178
Toledo, 2012, CSF biomarkers cutoffs: the importance of coincident neuropathological diseases, Acta Neuropathol, 124, 23, 10.1007/s00401-012-0983-7
Jack, 2010, Brain beta-amyloid measure and magnetic resonance imaging atophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease, Brain, 133, 3336, 10.1093/brain/awq277
Klunk WE, Cohen A, Bi W, et al. Why we need two cutoffs for amyloid-imaging: early versus Alzheimer's-like amyloid-positivity. Alzheimer's Association International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 03-12-03.
Rentz, 2010, Cognition, reserve, and amyloid deposition in normal aging, Ann Neurol, 67, 353, 10.1002/ana.21904
Vemuri, 2011, Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition, Brain, 134, 1479, 10.1093/brain/awr049
Reed, 2010, Measuring cognitive reserve based on the decomposition of episodic memory variance, Brain, 133, 2196, 10.1093/brain/awq154
Roe, 2008, Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake, Arch Neurol, 65, 1467, 10.1001/archneur.65.11.1467
Vemuri P, Lesnick T, Przybelski S, et al. Effect of lifestyle activities on AD biomarkers and cognition. Ann Neurol (in press).
Knopman, 2012, Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease, Neurology, 78, 1576, 10.1212/WNL.0b013e3182563bbe
Bateman R. Dominantly inherited Alzheimer network clinical trials: a model for prevention trials. Alzheimer's Association International Conference; Paris, France; July 16–21, 2011. S680.
Donohue M, Aisen PS, Dartigues J, Jacqmin-Gadda H, Gamst A, Le Gogg M. Validating Alzheimer's pathological cascade by merging ADNI with PAQUID. Alzheimer's Assoication International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 04-01-03.
Jedynak BM, Liu B, Lang A, et al. Sample size comparisons in ADNI: a case for the Alzheimer's disease progression scale. Alzheimer's Association International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 04-01-06.
Mungas D, Jones R, Tommet D. Sequencing of CSF abeta and tau, brain structure and function, and cognition in Alzheimer's disease. American Academy of Neurology Annual Meeting; New Orleans, LA; April 21–28, 2012. PD1.0003.
Braak, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol Aging, 18, 351, 10.1016/S0197-4580(97)00056-0
Braak, 2011, The pathological process underlying Alzheimer's disease in individuals under thirty, Acta Neuropathol, 121, 171, 10.1007/s00401-010-0789-4
Liu, 2012, Trans-synaptic spread of tau pathology in vivo, PLoS One, 7, e31302, 10.1371/journal.pone.0031302
de Calignon, 2012, Propagation of tau pathology in a model of early Alzheimer's disease, Neuron, 73, 685, 10.1016/j.neuron.2011.11.033
Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994
Small, 2008, Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis, Neuron, 60, 534, 10.1016/j.neuron.2008.11.007
Mesulam, 1999, Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles, Neuron, 24, 521, 10.1016/S0896-6273(00)81109-5
Duyckaerts, 2011, Tau pathology in children and young adults: can you still be unconditionally baptist?, Acta Neuropathol, 121, 145, 10.1007/s00401-010-0794-7
Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease, Ann Neurol, 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Musiek, 2012, Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement, Curr Opin Neurol, 25, 715, 10.1097/WCO.0b013e32835a30f4
Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature, 349, 704, 10.1038/349704a0
Hutton, 1998, Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17, Nature, 393, 702, 10.1038/31508
Jonsson, 2012, A mutation in APP protects against Alzheimer's disease and age-related cognitive decline, Nature, 488, 96, 10.1038/nature11283
Reiman, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia, Proc Natl Acad Sci USA, 101, 284, 10.1073/pnas.2635903100
Scarmeas, 2003, APOE genotype and cerebral blood flow in healthy young individuals, JAMA, 290, 1581, 10.1001/jama.290.12.1581
Morris, 2010, APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging, Ann Neurol, 67, 122, 10.1002/ana.21843
Vemuri, 2010, Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease, Ann Neurol, 67, 308, 10.1002/ana.21953
Bu, 2009, Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy, Nat Rev Neurosci, 10, 333, 10.1038/nrn2620
Dumanis, 2009, ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo, J Neurosci, 29, 15317, 10.1523/JNEUROSCI.4026-09.2009
Buckner, 2005, Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory, J Neurosci, 25, 7709, 10.1523/JNEUROSCI.2177-05.2005
Greicius, 2004, Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI, Proc Natl Acad Sci USA, 101, 4637, 10.1073/pnas.0308627101
Buckner, 2009, Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease, J Neurosci, 29, 1860, 10.1523/JNEUROSCI.5062-08.2009
Jones, 2011, Age-related changes in the default mode network are more advanced in Alzheimer disease, Neurology, 77, 1524, 10.1212/WNL.0b013e318233b33d
Seeley, 2009, Neurodegenerative diseases target large-scale human brain networks, Neuron, 62, 42, 10.1016/j.neuron.2009.03.024
Mormino, 2011, Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging, Cereb Cortex, 21, 2399, 10.1093/cercor/bhr025
Machulda, 2011, Effect of APOE ɛ4 status on intrinsic network connectivity in cognitively normal elderly subjects, Arch Neurol, 68, 1131, 10.1001/archneurol.2011.108
Sperling, 2009, Amyloid deposition is associated with impaired default network function in older persons without dementia, Neuron, 63, 178, 10.1016/j.neuron.2009.07.003
Sheline, 2010, APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42, J Neurosci, 30, 17035, 10.1523/JNEUROSCI.3987-10.2010
Filippini, 2009, Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele, Proc Natl Acad Sci USA, 106, 7209, 10.1073/pnas.0811879106
Chhatwal J, Schultz A, Johnson K, et al. Disrupted functional connectivity in autosomal dominant Alzheimer's Disease: preliminary findings from the DIAN study. Alzheimer's Association International Conference; Vancouver, Canada; July 14–19, 2012. Abstract 02-06-01.
Bero, 2011, Neuronal activity regulates the regional vulnerability to amyloid-beta deposition, Nat Neurosci, 14, 750, 10.1038/nn.2801
Jagust, 2011, Lifespan brain activity, beta-amyloid, and Alzheimer's disease, Trends Cogn Sci, 15, 520, 10.1016/j.tics.2011.09.004
Fodero-Tavoletti, 2011, 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease, Brain, 134, 1089, 10.1093/brain/awr038
Hu, 2012, Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease, Neurology, 79, 897, 10.1212/WNL.0b013e318266fa70
Whitwell, 2007, 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease, Brain, 130, 1777, 10.1093/brain/awm112
Vemuri, 2008, Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies, Neuroimage, 39, 1186, 10.1016/j.neuroimage.2007.09.073
Landau, 2010, Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, 230, 10.1212/WNL.0b013e3181e8e8b8
Villain, 2010, Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease, Brain, 133, 3301, 10.1093/brain/awq203